BACKGROUND: Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized. METHODS: To address this question, HAART initiators enrolled in the Multicenter AIDS Cohort Study were retrospectively analyzed. Patients were classified by hepatitis B category based on serology at the time of HAART initiation. The association of CH-B with mortality, AIDS-defining illnesses, CD4 cell rise, and HIV suppression was assessed using regression analysis. RESULTS: Of 816 men followed for a median of 7 years on HAART, 350 were never hepatitis B virus (HBV) infected, 357 had past infection, 45 had CH-B, and 64 were only core-antibody positive. Despite HAART, AIDS-related mortality was the most common cause of death [8.3/1000 person-years (PYs)]. It was highest in those with CH-B (17/1000 PYs, 95% confidence interval 7.3, 42) and lowest among never HBV infected (2.9/1000 PYs, 95% confidence interval 1.4, 6.4). In a multivariable model, patients with CH-B had a 2.7-fold higher incidence of AIDS-related mortality compared with those never infected (P = 0.08). Non-AIDS-related mortality was also highest among those with CH-B (22/1000 PYs), primarily due to liver disease (compared to never infected, adjusted hazard ratio 4.1, P = 0.04). There was no significant difference in AIDS-defining events, HIV RNA suppression, and CD4 cell increase. CONCLUSION: In HIV-infected patients receiving long-term HAART, HBV status did not influence HIV suppression or CD4 cell increase. However, mortality was highest among those with CH-B and was mostly due to liver disease despite HBV-active HAART. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
BACKGROUND:Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized. METHODS: To address this question, HAART initiators enrolled in the Multicenter AIDS Cohort Study were retrospectively analyzed. Patients were classified by hepatitis B category based on serology at the time of HAART initiation. The association of CH-B with mortality, AIDS-defining illnesses, CD4 cell rise, and HIV suppression was assessed using regression analysis. RESULTS: Of 816 men followed for a median of 7 years on HAART, 350 were never hepatitis B virus (HBV) infected, 357 had pastinfection, 45 had CH-B, and 64 were only core-antibody positive. Despite HAART, AIDS-related mortality was the most common cause of death [8.3/1000 person-years (PYs)]. It was highest in those with CH-B (17/1000 PYs, 95% confidence interval 7.3, 42) and lowest among never HBV infected (2.9/1000 PYs, 95% confidence interval 1.4, 6.4). In a multivariable model, patients with CH-B had a 2.7-fold higher incidence of AIDS-related mortality compared with those never infected (P = 0.08). Non-AIDS-related mortality was also highest among those with CH-B (22/1000 PYs), primarily due to liver disease (compared to never infected, adjusted hazard ratio 4.1, P = 0.04). There was no significant difference in AIDS-defining events, HIV RNA suppression, and CD4 cell increase. CONCLUSION: In HIV-infectedpatients receiving long-term HAART, HBV status did not influence HIV suppression or CD4 cell increase. However, mortality was highest among those with CH-B and was mostly due to liver disease despite HBV-active HAART. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
Authors: Miguel Goicoechea; Davey M Smith; Lin Liu; Susanne May; Allan R Tenorio; Caroline C Ignacio; Alan Landay; Richard Haubrich Journal: J Infect Dis Date: 2006-05-18 Impact factor: 5.226
Authors: Ronald J Bosch; Rui Wang; Florin Vaida; Michael M Lederman; Mary A Albrecht Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Rochelle P Walensky; A David Paltiel; Elena Losina; Lauren M Mercincavage; Bruce R Schackman; Paul E Sax; Milton C Weinstein; Kenneth A Freedberg Journal: J Infect Dis Date: 2006-06-01 Impact factor: 5.226
Authors: L H Omland; N Weis; P Skinhøj; Al Laursen; P B Christensen; H I Nielsen; A Møller; F Engsig; H T Sørensen; N Obel Journal: HIV Med Date: 2008-05 Impact factor: 3.180
Authors: James W T Cohen Stuart; Marieke Velema; Rob Schuurman; Charles A B Boucher; Andy I M Hoepelman Journal: J Med Virol Date: 2009-03 Impact factor: 2.327
Authors: Vincent Lo Re; Craig W Newcomb; Dena M Carbonari; Jason A Roy; Keri N Althoff; Mari M Kitahata; K Rajender Reddy; Joseph K Lim; Michael J Silverberg; Angel M Mayor; Michael A Horberg; Edward R Cachay; Gregory D Kirk; Mark Hull; John Gill; Timothy R Sterling; Jay R Kostman; Marion G Peters; Richard D Moore; Marina B Klein; H Nina Kim Journal: J Acquir Immune Defic Syndr Date: 2019-09-01 Impact factor: 3.731
Authors: Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte Journal: BMC Public Health Date: 2010-03-01 Impact factor: 3.295
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988